Feb 17, 2026 (PRISM News via COMTEX) --
Ocular Therapeutix (NASDAQ: OCUL) experienced a sharp 35% drop in its stock price on Tuesday, despite reporting seemingly positive outcomes from its Phase 3 superiority trial for AXPAXLI, a treatment for wet age-related macular degeneration (wet AMD).
The biopharmaceutical company announced that AXPAXLI successfully met its primary endpoint in the SOL-1 trial, demonstrating superiority over aflibercept in maintaining vision at Week 36. Specifically, 74.1% of participants in the AXPAXLI group maintained vision at this timepoint, reflecting a 17.5% risk difference compared to the aflibercept group (p=0.0006). Furthermore, the trial revealed that 65.9% of AXPAXLI-treated patients maintained vision at Week 52, with 68.8% remaining rescue-free at that stage. Importantly, the treatment was generally well-tolerated, with no treatment-related ocular serious adverse events reported.
Building on these results, Ocular Therapeutix plans to submit a New Drug Application (NDA) based on the SOL-1 data, pending discussions with the FDA. If approved, AXPAXLI could become the first tyrosine kinase inhibitor available for wet AMD treatment.
However, despite these promising findings, investor sentiment took a negative turn. Concerns over certain aspects of the data or potential regulatory challenges appear to have overshadowed the trial’s success, leading to the significant stock decline. The company is also conducting the complementary SOL-R Phase 3 non-inferiority trial, with topline data expected in the first quarter of 2027.
Looking ahead, Ocular Therapeutix plans to present detailed results from the SOL-1 trial at the 49th Macula Society Annual Meeting later this month. This presentation may provide further insights into the trial outcomes and address lingering investor concerns.
For more information please visit www.ocutx.com.
The post Ocular Therapeutix Stock Plummets Following Wet AMD Trial Results appeared first on PRISM MarketView.
COMTEX_473695718/2927/2026-02-17T09:30:55
